FDA Grants Orphan Drug Designation to SignaBlok's TREM-1 Inhibitor for Retinopathy of Prematurity
核心洞察
The FDA has granted orphan drug designation to SignaBlok (搜索)'s TREM-1 peptide inhibitor (搜索) for treating retinopathy of prematurity (搜索), a rare eye condition affecting premature infants.
The novel therapy uses a ligand-independent mechanism targeting the TREM-1 (搜索) receptor to address inflammation amplification, offering a potential alternative to current treatments like surgery and anti-VEGF injections.
Preclinical studies in mouse models demonstrated up to 95% reduction in retinal neovascularization, with data to be presented at the upcoming ARVO meeting in May.
The FDA has granted orphan drug designation to SignaBlok (搜索)'s triggering receptor expressed on myeloid cells 1 (TREM-1 (搜索)) peptide inhibitor for the treatment of retinopathy of prematurity (搜索) (ROP), marking a significant regulatory milestone for the Massachusetts-based biotechnology company's novel therapeutic approach.
Addressing Critical Unmet Medical Need
Current therapeutic options for ROP, including eye surgery, laser photocoagulation, and anti-VEGF drug injections, present significant limitations. "Current therapeutic options are harmful, do not cure, have a high risk of serious complications and are often ineffective, suggesting an unmet need for new therapies," said Alexander B. Sigalov, PhD, president and founder of SignaBlok (搜索).
The company's approach targets TREM-1 (搜索), an inflammation amplifier that plays a critical role in ROP development by magnifying inflammatory responses in innate immune cells such as macrophages. This receptor has been challenging to clinically target "due to multiple and unknown TREM-1 ligands."
Novel Mechanism of Action
SignaBlok (搜索)'s inhibitor addresses this challenge through a "new, ligand-independent mechanism of action" utilizing the company's proprietary Signaling Chain HOmoOLiguomerization (SCHOOL) technology. Unlike traditional approaches that block ligands outside the cell, SCHOOL targets receptors on immune cells to disrupt intracellular signaling, working to modulate signaling at the receptor complex level within the membrane signaling process.
The therapeutic employs a targeted peptide delivery platform that packages SCHOOL-designed peptides into lipopeptide complexes or nanoparticle-like carriers. This system targets specific immune cells, protects peptides within the body, and enables systemic administration while ensuring drug stability and cell specificity.
Promising Preclinical Results
The TREM-1 (搜索) inhibitor has undergone evaluation in an oxygen-induced retinopathy (搜索) (OIR) mouse model of ROP. The company reported that the inhibitor, described as a "non-toxic and well-tolerable ligand-independent TREM-1 inhibitor," significantly reduced retinal neovascularization by up to 95% in the retinas of mice with OIR during systematic administration in both preventive and therapeutic studies.
Additional preclinical data suggested the TREM-1 (搜索) inhibitor could "restore retinal function and preserve vision," though detailed results have not been made publicly available.
Regulatory Benefits and Future Development
The orphan drug designation qualifies SignaBlok (搜索) for several development incentives, including tax credits for qualified clinical trials, prescription drug user fee exemptions, and potential seven-year market exclusivity following approval. Orphan drug status is granted to treatments for rare diseases affecting fewer than 200,000 people in the United States.
"Orphan drug designation for ROP represents a significant milestone in further development of this therapy," Sigalov noted. "Importantly, a unique mechanism of action of our inhibitor significantly reduces the risk of drug failure in clinical trials, creating hope for premature babies affected by ROP."
SignaBlok (搜索) plans to present its first batch of preclinical efficacy, pharmacokinetic, and tolerability data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting scheduled for May 3-7 in Denver, Colorado. The company reported that the inhibitor's performance was "favorable" in these studies.